TFA EVIDENCE LIBRARY

Science and intellectual property

Explore the basis for TFA-01 development, from published research on Antcin A’s mechanism to preliminary company studies, formal research plans, and related technology patents.

PEER-REVIEWED · PATENT RECORDS

01 · Therapeutic Rationale & Scientific Evidence

A drug candidate with the potential to replace corticosteroids

Corticosteroids have well-established therapeutic value, but the challenges of repeated or prolonged use create demand for new treatments. TFA-01 is an Antcin A-based drug candidate being studied for its potential to provide anti-inflammatory activity with an improved long-term benefit-risk profile.

Treatment Need

Long-term treatment requires more than efficacy alone

Chronic inflammatory conditions require ongoing management. TFA aims to develop a new treatment option and evaluate its potential for repeated use.

Published Research

Antcin A offers a scientific starting point

A 2011 cell study reported that Antcin A induced nuclear translocation of the glucocorticoid receptor (GR)—movement of the receptor from the cytoplasm into the nucleus.

Read the original study

Company Research

Advancing published findings through TFA’s research program

Preliminary in vitro research by Dr. Huang’s team observed anti-inflammatory signals, supporting further work on dosing, formulation, safety, and canine OA.

GR nuclear translocation and in vitro findings support further development; potential as an alternative to corticosteroids requires validation in formal studies.

Explore the scientific evidence

Evidence boundaries

Preclinical research does not establish clinical benefit, and patents do not imply drug approval. Each item states its limits.

6peer-reviewed publications

Mechanism, absorption and preclinical models.

2preliminary datasets

A preliminary 14-day repeat-dose study in female rats and exploratory observations in 15 dogs.

4patent jurisdictions

Patents across Taiwan, China, Japan and the U.S.

HOW TO READ THE EVIDENCE

How published scientific findings inform TFA’s drug research

The 2011 GR nuclear translocation study provides a starting point. TFA is building on preliminary in vitro findings and canine observations to advance formal safety, formulation, and clinical studies.

Keep molecules distinct

Antcin A, Antcin K and Antrocin are different compounds. Findings for one cannot be applied to another.

Label every model

General cell models, Caco-2 absorption models, animal studies, and human evidence represent different levels; each publication is labeled accordingly.

Keep conclusions within the evidence

Mechanistic signals are not described as clinical benefit, and exploratory findings are not described as approved uses.

DEVELOPMENT EVIDENCE MAP

The evidence supporting TFA-01 development

Each of the five development workstreams identifies the available evidence and what remains to be verified.

Molecule, mechanism & rights

Published research foundation / program validation underway

Published studies support GR/GRα-related signaling by Antcin A in defined models. TFA is assessing how those findings apply to its current test articles, batches and canine OA development program.

Next milestoneComplete candidate test-article and batch definition and strengthen program-level pharmacology relevant to canine osteoarthritis.LimitationsAvailable studies do not establish direct biochemical binding between Antcin A and GR, canine or human clinical efficacy, program-specific pharmacokinetic parameters, or drug approval.View progress details

CMC & controlled supply

Sourcing foundation in place / specifications and batch bridging underway

Research on strains from multiple sources and their Antcin A content supports controlled cultivation, strain selection, purification, analytical testing and formulation development.

Next milestoneComplete physicochemical validation of the nanoformulation, then advance formal specifications, batch consistency and process scale-up.LimitationsFormal specifications, COAs, batch consistency, commercial scale-up and GMP validation are not complete. The nanoformulation remains under physicochemical validation, and final formulation specifications have not yet been established.View progress details

Safety & toxicology

Preliminary 14-day repeat-dose study completed | Formal studies advancing

A 14-day repeat-dose preliminary toxicology study in female rats is complete and a report is available to inform later study design. The Graduate Institute of Animal Vaccine Technology is advancing target-animal safety, toxicology, residue and formulation-related research.

Next milestoneComplete the subsequent regulatory toxicology reports and establish the safe dose range for the purified candidate drug substance and final product under this development program.LimitationsThe preliminary screen was not GLP regulatory toxicology or a long-term safety study. It does not establish canine safety, long-term safety, or the safety of purified Antcin A or a final product.View progress details

Canine OA clinical development

First-stage agreement signed / preliminary cell testing underway

TFA completed uncontrolled exploratory observations in 15 dogs. The first-stage canine osteoarthritis research agreement has been signed, and preliminary cell-based testing is underway ahead of a standardized study.

Next milestoneComplete the canine OA study under a protocol with prespecified endpoints and a statistical analysis plan, and prepare the study report.LimitationsThe 15-dog internal exploration was not a regulatory study and lacks verifiable formal start and end dates, a full protocol, prespecified endpoints, statistical analysis and a signed report. It does not establish efficacy, safety, equivalence or superiority. Launching the later research collaboration is not the same as study completion or a new conclusion.View progress details

Regulatory strategy & commercialization

Taiwan advancing / U.S. CVM planning

TFA is assembling data for a veterinary drug application in Taiwan and planning its U.S. CVM strategy. Partnership and licensing opportunities will be evaluated as the supporting data develop.

Next milestoneObtain regulatory feedback on study design, process specifications and remaining data gaps, then develop a submission plan.LimitationsRegulatory acceptance of the data, acceptance of the application for review, drug approval, launch timing and commercial outcomes remain uncertain.View progress details

CORE PUBLISHED LITERATURE